Composition for use in treatment of a biofilm in a subject
Provided is DHA, or a composition comprising DHA, for use in treatment of a biofilm in a subject and for use in treatment of a disease or infection associated or caused by a biofilm in a subject.
1 . A method of treatment of a biofilm comprising Klebsiella pneumoniae and/or Enterococcus faecalis in a subject, the method comprising:
administering:
a) an effective amount of DHA or a derivative thereof, and
b) a macrolide antibiotic;
to the subject.
2 . The method of claim 1 , wherein the macrolide antibiotic is selected from azithromycin, clarithromycin, erythromycin, and roxithromycin.
3 . The method of claim 1 , wherein the subject is one with an implanted or indwelling medical device, or an immunocompromised subject, or a subject that will undergo surgery to receive an implanted or indwelling medical device.
4 . The method of claim 1 wherein the subject is one with an implanted or indwelling medical device, or a subject that will undergo surgery to receive an implanted or indwelling medical device, and
wherein the medical device is selected from the group consisting of:
prosthetic heart valves, orthopaedic implants, intravascular catheters, artificial hearts, left ventricular assist devices, cardiac pacemakers, defibrillator, vascular prostheses, cerebrospinal fluid shunts, urinary catheters, ocular prostheses, contact lenses, and intrauterine contraceptive device.
5 . The method of claim 1 , wherein the DHA is in the form of a pharmaceutical composition comprising DHA and one or more pharmaceutically acceptable excipients.
6 . The method of claim 1 , wherein the concentration of the DHA is from 1 μM to 200 μM.
7 . The method of claim 1 wherein the concentration of the DHA is from 6 μM to 100 μM.
8 . The method of claim 1 , wherein the biofilm is one in the lung, the heart, the skin, the eye, the gastrointestinal tract, and/or the urinary tract of the subject.
9 . The method of claim 1 , wherein the DHA and the macrolide antibiotic are administered simultaneously.
10 . The method of claim 1 , wherein when the DHA and the macrolide antibiotic are administered in one composition.
11 . The method of claim 1 , wherein the macrolide antibiotic is erythromycin.
12 . The method of claim 1 , wherein the DNA and the macrolide antibiotic are administered sequentially.
13 . The method of claim 1 , wherein when the DHA and macrolide antibiotic are administered in separate compositions.
14 . A method of treatment of a disease or condition associated with Klebsiella pneumoniae or Enterococcus faecalis biofilm formation in a subject, comprising administration of n DHA and a macrolide antibiotic to the subject.
15 . The method of claim 14 , wherein the macrolide antibiotic is selected from azithromycin, clarithromycin, erythromycin, and roxithromycin.
16 . The method of claim 14 , wherein the DHA and the macrolide antibiotic are administered simultaneously.
17 . The method of claim 14 , wherein when the DHA and the macrolide antibiotic are administered in one composition.
18 . The method of claim 14 , wherein the DNA and the macrolide antibiotic are administered sequentially.
19 . The method of claim 14 , wherein when the DHA and macrolide antibiotic are administered in separate compositions.